Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection

International Journal of Food Sciences and Nutrition

Volumn 68, Issue 1, 2017, Pages 18-27

  Godos, Justyna ^a   Federico, Alessandro ^b   Dallio, Marcello ^b   Scazzina, Francesca ^c  

^a UNIVERSITY OF CATANIA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

dietary intake; Mediterranean diet; nonalcoholic fatty liver disease; polyphenols; polyunsaturated fatty acids; whole grain

Indexed keywords

ANIMAL; BIOLOGICAL MODEL; EVIDENCE BASED MEDICINE; GLOBAL HEALTH; HUMAN; MEDITERRANEAN DIET; METABOLIC SYNDROME X; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR;

ANIMALS; DIET, MEDITERRANEAN; EVIDENCE-BASED MEDICINE; GLOBAL HEALTH; HUMANS; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84980347995     PISSN: 09637486     EISSN: 14653478     Source Type: Journal    
DOI: 10.1080/09637486.2016.1214239     Document Type: Article

References (98)

1. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD., 2001. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis:results of a pilot study. Am J Gastroenterol. 96:2711–2717.
2. Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S., 2014. Alimentary regimen in non-alcoholic fatty liver disease:Mediterranean diet. World J Gastroenterol. 20:16831–16840.
3. Afshin A, Micha R, Khatibzadeh S, Mozaffarian D., 2014. Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes:a systematic review and meta-analysis. Am J Clin Nutr. 100:278–288.
4. Aguirre L, Portillo MP, Hijona E, Bujanda L., 2014. Effects of resveratrol and other polyphenols in hepatic steatosis. World J Gastroenterol. 20:7366–7380.
5. Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, Jalali P, Kandasamy T, Prayitno N, Sherman M, et al. 2008. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD):a cross-sectional study. J Hepatol. 48:300–307.
6. Arendt BM, Allard JP., 2011. Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease:is the combination required? Am J Gastroenterol. 106:78–80.
7. Assy N, Nassar F, Nasser G, Grosovski M., 2009. Olive oil consumption and non-alcoholic fatty liver disease. World J Gastroenterol. 15:1809–1815.
8. Augustin LS, Kendall CW, Jenkins DJ, Willett WC, Astrup A, Barclay AW, Bjorck I, Brand-Miller JC, Brighenti F, Buyken AE, et al. 2015. Glycemic index, glycemic load and glycemic response:An International Scientific Consensus Summit from the International Carbohydrate Quality Consortium (ICQC). Nutr Metab Cardiovasc Dis. 25:795–815.
9. Aune D, Norat T, Romundstad P, Vatten LJ., 2013. Whole grain and refined grain consumption and the risk of type 2 diabetes:a systematic review and dose-response meta-analysis of cohort studies. Eur J Epidemiol. 28:845–858.
10. Baffy G., 2013. Hepatocellular carcinoma in non-alcoholic fatty liver disease:epidemiology, pathogenesis, and prevention. J Clin Transl Hepatol. 1:131–137.
11. Barrera F, George J., 2014. The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis. 18:91–112.
12. Bellentani S, Marino M., 2009. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 8:S4–S8.
13. Bodinham CL, Hitchen KL, Youngman PJ, Frost GS, Robertson MD., 2011. Short-term effects of whole-grain wheat on appetite and food intake in healthy adults:a pilot study. Br J Nutr. 106:327–330.
14. Bozic MA, Subbarao G, Molleston JP., 2013. Pediatric nonalcoholic fatty liver disease. Nutr Clin Pract. 28:448–458.
15. Bozzetto L, Prinster A, Annuzzi G, Costagliola L, Mangione A, Vitelli A, Mazzarella R, Longobardo M, Mancini M, Vigorito C, et al. 2012. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care. 35:1429–1435.
16. Brighenti F, Benini L, Del Rio D, Casiraghi C, Pellegrini N, Scazzina F, Jenkins DJ, Vantini I., 2006. Colonic fermentation of indigestible carbohydrates contributes to the second-meal effect. Am J Clin Nutr. 83:817–822.
17. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G., 2005. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 100:1082–1090.
18. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, et al. 2002. Expanding the natural history of nonalcoholic steatohepatitis:from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 123:134–140.
19. Buscemi S, Sprini D, Grosso G, Galvano F, Nicolucci A, Lucisano G, Massenti FM, Amodio E, Rini GB., 2014. Impact of lifestyle on metabolic syndrome in apparently healthy people. Eat Weight Disord. 19:225–232.
20. Del Rio D, Costa LG, Lean ME, Crozier A., 2010. Polyphenols and health:what compounds are involved? Nutr Metab Cardiovasc Dis. 20:1–6.
21. Demir M, Lang S, Steffen HM., 2015. Nonalcoholic fatty liver disease:current status and future directions. J Dig Dis. 16:541–557.
22. Di Minno MN, Russolillo A, Lupoli R, Ambrosino P, Di Minno A, Tarantino G., 2012. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol. 18:5839–5847.
23. Di Sario A, Candelaresi C, Omenetti A, Benedetti A., 2007. Vitamin E in chronic liver diseases and liver fibrosis. Vitam Horm. 76:551–573.
24. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ., 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 115:1343–1351.
25. Estruch R, Salas-Salvado J., 2013. Towards an even healthier Mediterranean diet. Nutr Metab Cardiovasc Dis. 23:1163–1166.
26. Ferramosca A, Savy V, Zara V., 2008. Olive oil increases the hepatic triacylglycerol content in mice by a distinct influence on the synthesis and oxidation of fatty acids. Biosci Biotechnol Biochem. 72:62–69.
27. Ferramosca A, Zara V., 2014. Modulation of hepatic steatosis by dietary fatty acids. World J Gastroenterol. 20:1746–1755.
28. Grosso G, Bei R, Mistretta A, Marventano S, Calabrese G, Masuelli L, Giganti MG, Modesti A, Galvano F, Gazzolo D., 2013a. Effects of vitamin C on health:a review of evidence. Front Biosci (Landmark Ed). 18:1017–1029.
29. Grosso G, Galvano F, Mistretta A, Marventano S, Nolfo F, Calabrese G, Buscemi S, Drago F, Veronesi U, Scruderi A., 2013b. Red orange:experimental models and epidemiological evidence of its benefits on human health. Oxid Med Cell Longev. 2013:157240.
30. Grosso G, Marventano S, Buscemi S, Scuderi A, Matalone M, Platania A, Giorgianni G, et al. 2013c. Factors associated with adherence to the Mediterranean diet among adolescents living in Sicily, Southern Italy. Nutrients. 5:4908–4923.
31. Grosso G, Marventano S, Galvano F, Pajak A, Mistretta A., 2014a. Factors associated with metabolic syndrome in a mediterranean population:role of caffeinated beverages. J Epidemiol. 24:327–333.
32. Grosso G, Marventano S, Giorgianni G, Raciti T, Galvano F, Mistretta A., 2014b. Mediterranean diet adherence rates in Sicily, southern Italy. Public Health Nutr. 17:2001–2009.
33. A comprehensive meta-analysis on evidence of mediterranean diet and cardiovascular disease: are individual components equal?
34. Grosso G, Stepaniak U, Micek A, Stefler D, Bobak M, Pajak A., 2016. Dietary polyphenols are inversely associated with metabolic syndrome in Polish adults of the HAPIEE study. Eur J Nutr. [Epub ahead of print]. doi:10.1007/s00394-016-1187-z.
35. Grosso G, Stepaniak U, Micek A, Topor-Madry R, Stefler D, Szafraniec K, Bobak M, Pajak A., 2015b. A Mediterranean-type diet is associated with better metabolic profile in urban Polish adults:results from the HAPIEE study. Metabolism. 64:738–746.
36. Grosso G, Stepaniak U, Topor-Madry R, Szafraniec K, Pajak A., 2014c. Estimated dietary intake and major food sources of polyphenols in the Polish arm of the HAPIEE study. Nutrition. 30:1398–1403.
37. Grosso G, Yang J, Marventano S, Micek A, Galvano F, Kales SN., 2015c. Nut consumption on all-cause, cardiovascular, and cancer mortality risk:a systematic review and meta-analysis of epidemiologic studies. Am J Clin Nutr. 101:783–793.
38. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S., 2003. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 98:2485–2490.
39. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A., 2001. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis:a pilot study. Aliment Pharmacol Ther. 15:1667–1672.
40. Hirsch S, Poniachick J, Avendano M, Csendes A, Burdiles P, Smok G, Diaz JC, de la Maza MP., 2005. Serum folate and homocysteine levels in obese females with non-alcoholic fatty liver. Nutrition. 21:137–141.
41. Hollaender PL, Ross AB, Kristensen M., 2015. Whole-grain and blood lipid changes in apparently healthy adults:a systematic review and meta-analysis of randomized controlled studies. Am J Clin Nutr. 102:556–572.
42. Horton JD, Goldstein JL, Brown MS., 2002. SREBPs:activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 109:1125–1131.
43. Hussein O, Grosovski M, Lasri E, Svalb S, Ravid U, Assy N., 2007. Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. World J Gastroenterol. 13:361–368.
44. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I., 2003. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology. 38:123–132.
45. Isaksson H, Fredriksson H, Andersson R, Olsson J, Aman P., 2009. Effect of rye bread breakfasts on subjective hunger and satiety:a randomized controlled trial. Nutr J. 8:39.
46. Isaksson H, Rakha A, Andersson R, Fredriksson H, Olsson J, Aman P., 2011. Rye kernel breakfast increases satiety in the afternoon–an effect of food structure. Nutr J. 10:31.
47. Isaksson H, Sundberg B, Aman P, Fredriksson H, Olsson J., 2008. Whole grain rye porridge breakfast improves satiety compared to refined wheat bread breakfast. Food Nutr Res. 52. doi:10.3402/fnr.v52i0.1809.
48. Isaksson H, Tillander I, Andersson R, Olsson J, Fredriksson H, Webb DL, Aman P., 2012. Whole grain rye breakfast - sustained satiety during three weeks of regular consumption. Physiol Behav. 105:877–884.
49. Jenkins DJ, Wolever TM, Kalmusky J, Guidici S, Giordano C, Patten R, Wong GS, et al. 1987. Low-glycemic index diet in hyperlipidemia:use of traditional starchy foods. Am J Clin Nutr. 46:66–71.
50. Ju SY, Jeong HS, Kim do H., 2014. Blood vitamin D status and metabolic syndrome in the general adult population:a dose-response meta-analysis. J Clin Endocrinol Metab. 99:1053–1063.
51. Jump DB., 2008. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol. 19:242–247.
52. Kwak JH, Paik JK, Kim OY, Jang Y, Lee SH, Ordovas JM, Lee JH., 2011. FADS gene polymorphisms in Koreans:association with omega6 polyunsaturated fatty acids in serum phospholipids, lipid peroxides, and coronary artery disease. Atherosclerosis. 214:94–100.
53. Levene AP, Goldin RD., 2012. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology. 61:141–152.
54. Li M, Fan Y, Zhang X, Hou W, Tang Z., 2014. Fruit and vegetable intake and risk of type 2 diabetes mellitus:meta-analysis of prospective cohort studies. BMJ Open. 4:e005497.
55. Liu S, Willett WC, Stampfer MJ, Hu FB, Franz M, Sampson L, Hennekens CH, Manson JE., 2000. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr. 71:1455–1461.
56. Madan K, Batra Y, Gupta DS, Chander B, Anand Rajan KD, Singh R, Panda SK, Acharya SK., 2005. Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. Indian J Gastroenterol. 24:251–255.
57. Marventano S, Kolacz P, Castellano S, Galvano F, Buscemi S, Mistretta A, Grosso G., 2015. A review of recent evidence in human studies of n-3 and n-6 PUFA intake on cardiovascular disease, cancer, and depressive disorders:does the ratio really matter? Int J Food Sci Nutr. 66:611–622.
58. Marx N, Duez H, Fruchart JC, Staels B., 2004. Peroxisome proliferator-activated receptors and atherogenesis:regulators of gene expression in vascular cells. Circ Res. 94:1168–1178.
59. Masterton GS, Plevris JN, Hayes PC., 2010. Review article:omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 31:679–692.
60. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Masciana R, Forgione A, Gabrieli ML, Perotti G, et al. 2009. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 49:1877–1887.
61. Miglio F, Rovati LC, Santoro A, Setnikar I., 2000. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung. 50:722–727.
62. Monteiro J, Leslie M, Moghadasian MH, Arendt BM, Allard JP, Ma DW., 2014. The role of n - 6 and n - 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease. Food Funct. 5:426–435.
63. Nakano T, Cheng YF, Lai CY, Hsu LW, Chang YC, Deng JY, Huang YZ, Honda H, Chen KD, Wang CC, et al. 2011. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol. 55:415–425.
64. Pan MH, Lai CS, Tsai ML, Ho CT., 2014. Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. Mol Nutr Food Res. 58:147–171.
65. Parnell JA, Raman M, Rioux KP, Reimer RA., 2012. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 32:701–711.
66. Pawar A, Jump DB., 2003. Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatocytes. J Biol Chem. 278:35931–35939.
67. Pirozzi C, Lama A, Simeoli R, Paciello O, Pagano TB, Mollica MP, Di Guida F, Russo R, Magliocca S, Canani RB, et al. 2016. Hydroxytyrosol prevents metabolic impairment reducing hepatic inflammation and restoring duodenal integrity in a rat model of NAFLD. J Nutr Biochem. 30:108–115.
68. Pol K, Christensen R, Bartels EM, Raben A, Tetens I, Kristensen M., 2013. Whole grain and body weight changes in apparently healthy adults:a systematic review and meta-analysis of randomized controlled studies. Am J Clin Nutr. 98:872–884.
69. Postic C, Girard J., 2008. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance:lessons from genetically engineered mice. J Clin Invest. 118:829–838.
70. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, et al. 2007. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 46:1081–1090.
71. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G., 2010. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 53:372–384.
72. Rodriguez-Mateos A, Vauzour D, Krueger CG, Shanmuganayagam D, Reed J, Calani L, Mena P, Del Rio D, Crozier A., 2014. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds:an update. Arch Toxicol. 88:1803–1853.
73. Ross AB., 2012. Present status and perspectives on the use of alkylresorcinols as biomarkers of wholegrain wheat and rye intake. J Nutr Metab. 2012:462967.
74. Ross AB, Godin JP, Minehira K, Kirwan JP., 2013. Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. Int J Endocrinol. 2013:585876.
75. Ryan M, McInerney D, Owens D, Collins P, Johnson A, Tomkin GH., 2000. Diabetes and the Mediterranean diet:a beneficial effect of oleic acid on insulin sensitivity, adipocyte glucose transport and endothelium-dependent vasoreactivity. QJM. 93:85–91.
76. Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, O'dea K, et al. 2013. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 59:138–143.
77. Salomone F, Godos J, Zelber-Sagi S., 2016. Natural anti-oxidants for non-alcoholic fatty liver disease:molecular targets and clinical perspectives. Liver Int. 36:5–20.
78. Samara K, Liu C, Soldevila-Pico C, Nelson DR, Abdelmalek MF., 2006. Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation. Dig Dis Sci. 51:1226–1229.
79. Sato K, Arai H, Mizuno A, Fukaya M, Sato T, Koganei M, Sasaki H, Yamamoto H, Taketani Y, Doi T, Takeda E., 2007. Dietary palatinose and oleic acid ameliorate disorders of glucose and lipid metabolism in Zucker fatty rats. J Nutr. 137:1908–1915.
80. Sofi F, Casini A., 2014. Mediterranean diet and non-alcoholic fatty liver disease:new therapeutic option around the corner? World J Gastroenterol. 20:7339–7346.
81. Targher G, Scorletti E, Mantovani A, Byrne CD., 2013. Nonalcoholic fatty liver disease and reduced serum vitamin D(3) levels. Metab Syndr Relat Disord. 11:217–228.
82. Tremaroli V, Backhed F., 2012. Functional interactions between the gut microbiota and host metabolism. Nature. 489:242–249.
83. Valtuena S, Pellegrini N, Ardigo D, Del Rio D, Numeroso F, Scazzina F, Monti L, Zavaroni I, Brighenti F., 2006. Dietary glycemic index and liver steatosis. Am J Clin Nutr. 84:136–142.
84. Van De Wier B, Koek GH, Bast A, Haenen GR., 2015. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Crit Rev Food Sci Nutr. [Epub ahead of print]. doi:10.1080/10408398.2014.952399.1
85. Velasco N, Contreras A, Grassi B., 2014. The Mediterranean diet, hepatic steatosis and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 17:453–457.
86. Vera-Ramirez L, Perez-Lopez P, Varela-Lopez A, Ramirez-Tortosa M, Battino M, Quiles JL., 2013. Curcumin and liver disease. Biofactors. 39:88–100.
87. Vernon G, Baranova A, Younossi ZM., 2011. Systematic review:the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 34:274–285.
88. Vitaglione P, Napolitano A, Fogliano V., 2008. Cereal dietary fibre:a natural functional ingredient to deliver phenolic compounds into the gut. Trends Food Sci Technol. 19:451–463.
89. Volynets V, Kuper MA, Strahl S, Maier IB, Spruss A, Wagnerberger S, Konigsrainer A, Bischoff SC, Bergheim I., 2012. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci. 57:1932–1941.
90. Vos MB, Colvin R, Belt P, Molleston JP, Murray KF, Rosenthal P, Schwimmer JB, Tonascia J, Unalp A, Lavine JE. NASH CRN Research Group. 2012. Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr. 54:90–96.
91. Wallin A, Di Giuseppe D, Orsini N, Patel PS, Forouhi NG, Wolk A., 2012. Fish consumption, dietary long-chain n-3 fatty acids, and risk of type 2 diabetes:systematic review and meta-analysis of prospective studies. Diabetes Care. 35:918–929.
92. Weiss J, Rau M, Geier A., 2014. Non-alcoholic fatty liver disease:epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int. 111:447–452.
93. Xu J, Teran-Garcia M, Park JH, Nakamura MT, Clarke SD., 2001. Polyunsaturated fatty acids suppress hepatic sterol regulatory element-binding protein-1 expression by accelerating transcript decay. J Biol Chem. 276:9800–9807.
94. Yang X, Sheng W, Sun GY, Lee JC., 2011. Effects of fatty acid unsaturation numbers on membrane fluidity and alpha-secretase-dependent amyloid precursor protein processing. Neurochem Int. 58:321–329.
95. Zamora-Ros R, Knaze V, Rothwell JA, Hemon B, Moskal A, Overvad K, Tjonneland A, Kyro C, Fagherazzi G, Boutron-Ruault MC, et al. 2015. Dietary polyphenol intake in Europe:the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Nutr. 55:1359–1375.
96. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, Oren R., 2007. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD):a population based study. J Hepatol. 47:711–717.
97. Zelber-Sagi S, Ratziu V, Oren R., 2011. Nutrition and physical activity in NAFLD:an overview of the epidemiological evidence. World J Gastroenterol. 17:3377–3389.
98. Zhang M, Picard-Deland E, Marette A., 2013. Fish and marine omega-3 polyunsatured Fatty Acid consumption and incidence of type 2 diabetes:a systematic review and meta-analysis. Int J Endocrinol. 2013:501015.